

# M02

## Performance Standards for Antimicrobial Disk Susceptibility Tests

This standard covers the current recommended methods for disk susceptibility testing and criteria for quality control testing.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

## Performance Standards for Antimicrobial Disk Susceptibility Tests

Melvin P. Weinstein, MD  
Jean B. Patel, PhD, D(ABMM)  
Carey-Ann Burnham, PhD, D(ABMM)  
Shelley Campeau, PhD, D(ABMM)  
Patricia S. Conville, MS, MT(ASCP)  
Christopher Doern, PhD, D(ABMM)  
George M. Eliopoulos, MD  
Marcelo F. Galas  
Romney M. Humphries, PhD, D(ABMM)  
Stephen G. Jenkins, PhD, D(ABMM), F(AAM)  
Susan M. Kircher, MS, MT(ASCP)  
James S. Lewis II, PharmD, FIDSA

Brandi Limbago, PhD  
Amy J. Mathers, MD, D(ABMM)  
Tony Mazzulli, MD, FACP, FRCP(C)  
Susan D. Munro, CLS, MT(ASCP)  
Margaret Ordoñez Smith de Danies, PhD  
Robin Patel, MD  
Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA  
Michael Satlin, MD, MS  
Jana M. Swenson, MMSc  
Alexandra Wong, BS, MT(ASCP), SM  
Wayne F. Wang, MD, PhD  
Barbara L. Zimmer, PhD

### Abstract

Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism's identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents.

Various laboratory methods can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. In many medical microbiology laboratories, an agar disk diffusion method is used routinely for testing common, rapidly growing, and certain fastidious bacterial pathogens. Clinical and Laboratory Standards Institute standard M02—*Performance Standards for Antimicrobial Disk Susceptibility Tests* includes a series of procedures to standardize the way disk diffusion tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described.

The supplemental information (M100<sup>1</sup> tables) used with this standard represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk Susceptibility Tests*. 13th ed. CLSI standard M02 (ISBN 1-56238-834-7 [Print]; ISBN 1-56238-835-5 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Performance Standards for Antimicrobial Disk Susceptibility Tests*. 13th ed. CLSI standard M02. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

### **Previous Editions:**

July 1975, October 1979, December 1984, November 1988, April 1990, December 1993, January 1997, January 2000, January 2003, January 2006, January 2009, January 2012, January 2015

ISBN 1-56238-834-7 (Print)  
ISBN 1-56238-835-5 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 38, Number 1

## Committee Membership

### Consensus Council

**Carl D. Mottram, RRT, RPFT,**  
FAARC  
Chairholder  
Mayo Clinic  
USA

**Dennis J. Ernst, MT(ASCP),**  
NCPT(NCCT)  
Vice-Chairholder  
Center for Phlebotomy Education  
USA

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ)CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid Services  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Mary Lou Gantzer, PhD, FACB  
BioCore Diagnostics  
USA

Loralie J. Langman, PhD, DABCC, FACB,  
F-ABFT  
Mayo Clinic  
USA

Ross J. Molinaro, PhD,  
MLS(ASCP)CM, DABCC, FACB  
Siemens Healthcare Diagnostics, Inc.  
USA

Joseph Passarelli  
Roche Diagnostics Corporation  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of  
Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Subcommittee on Antimicrobial Susceptibility Testing

**Melvin P. Weinstein, MD**  
Chairholder  
Rutgers Robert Wood Johnson  
Medical School  
USA

**Jean B. Patel, PhD, D(ABMM)**  
Vice-Chairholder  
Centers for Disease Control and  
Prevention  
USA

George M. Eliopoulos, MD  
Beth Israel Deaconess Medical Center  
USA

Marcelo F. Galas  
Pan American Health Organization  
USA

Romney M. Humphries, PhD, D(ABMM)  
Accelerate Diagnostics  
USA

Stephen G. Jenkins, PhD, D(ABMM),  
F(AAM)  
Weill Cornell Medicine  
USA

James S. Lewis II, PharmD, FIDSA  
Oregon Health and Science University  
USA

Brandi Limbago, PhD  
Centers for Disease Control and Prevention  
USA

Amy J. Mathers, MD, D(ABMM)  
University of Virginia Medical Center  
USA

Tony Mazzulli, MD, FACP, FRCP(C),  
Mount Sinai Hospital  
Canada

Robin Patel, MD  
Mayo Clinic  
USA

Sandra S. Richter, MD, D(ABMM),  
FCAP, FIDSA  
Cleveland Clinic  
USA

Michael Satlin, MD, MS  
New York Presbyterian Hospital  
USA

Barbara L. Zimmer, PhD  
Beckman Coulter – West Sacramento  
USA

### Working Group on M02/M07 Revision

**Carey-Ann Burnham, PhD,  
D(ABMM)  
Co-Chairholder  
Washington University School of  
Medicine  
USA**

**Susan D. Munro, CLS, MT(ASCP)  
Co-Chairholder  
USA**

**Christopher Doern, PhD, D(ABMM)  
Committee Secretary  
Virginia Commonwealth University  
Health System  
USA**

Patricia S. Conville, MS, MT(ASCP)  
FDA Center for Devices and  
Radiological Health  
USA

Dwight J. Hardy, PhD  
University of Rochester Medical Center  
USA

Susan M. Kircher, MS, MT(ASCP)  
BD Diagnostic Systems  
USA

Margaret Ordoñez Smith de Danies, PhD  
Microbiology Institute of Colombia  
Colombia

Wayne F. Wang, MD, PhD  
Emory University Hospital  
USA

Alexandra Wong, BS, MT(ASCP), SM  
FDA Center for Devices and  
Radiological Health  
USA

### Working Group on AST Breakpoints

**George M. Eliopoulos, MD  
Co-Chairholder  
Beth Israel Deaconess Medical Center  
USA**

**James S. Lewis II, PharmD, FIDSA  
Co-Chairholder  
Oregon Health and Science University  
USA**

**Karen Bush, PhD  
Committee Secretary  
Indiana University  
USA**

Marcelo F. Galas  
Pan American Health Organization  
USA

Amy J. Mathers, MD, D(ABMM)  
University of Virginia Medical Center  
USA

David P. Nicolau, PharmD, FCCP,  
FIDSA  
Hartford Hospital  
USA

Robin Patel, MD  
Mayo Clinic  
USA

Michael Satlin, MD, MS  
New York Presbyterian Hospital  
USA

Audrey N. Schuetz, MD, MPH,  
D(ABMM)  
Mayo Clinic  
USA

Simone M. Shurland  
FDA Center for Devices  
and Radiological Health  
USA

Lauri D. Thrupp, MD  
University of California Irvine  
Medical Center  
USA

Hui Wang, MD  
Peking University People's  
Hospital  
China

Barbara L. Zimmer, PhD  
Beckman  
Coulter – West Sacramento  
USA

### Working Group on Methods Application and Interpretation

**Thomas J. Kirn, MD, PhD  
Co-Chairholder  
Rutgers Robert Wood Johnson  
Medical School  
USA**

**Brandi Limbago, PhD  
Co-Chairholder  
Centers for Disease Control and  
Prevention  
USA**

**Patricia J. Simner, PhD, D(ABMM)  
Committee Secretary  
Johns Hopkins  
Hospital - Pathology  
USA**

Darcie E. Carpenter, PhD, CIC, CEM  
Beckman Coulter, Inc.  
USA

Stephen G. Jenkins, PhD, D(ABMM),  
F(AAM)  
Weill Cornell Medicine  
USA

Kristie Johnson, PhD, D(ABMM)  
University of Maryland, Baltimore  
USA

Joseph Kuti, PharmD  
Hartford Hospital  
USA

Samir Patel, PhD, FCCM, D(ABMM)  
Public Health Ontario  
Canada

Virginia M. Pierce, MD  
Massachusetts General Hospital  
USA

Sandra S. Richter, MD, D(ABMM),  
FCAP, FIDSA  
Cleveland Clinic  
USA

Susan Sharp, PhD, D(ABMM), F(AAM)  
American Society for Microbiology  
USA

### Working Group on Methods Development and Standardization

<b>Dwight J. Hardy, PhD</b> Co-Chairholder University of Rochester Medical Center USA	William B. Brasso, BS BD Diagnostic Systems USA	Romney M. Humphries, PhD, D(ABMM) Accelerate Diagnostics USA
<b>Barbara L. Zimmer, PhD</b> Co-Chairholder Beckman Coulter – West Sacramento USA	Susan Butler-Wu, PhD, D(ABMM), SM(ASCP) LACUSC Medical Center USA	Laura M. Koeth, MT(ASCP) Laboratory Specialists, Inc. USA
<b>Katherine Sei, BS</b> Committee Secretary Beckman Coulter, Inc. USA	Jennifer Dien Bard, PhD, D(ABMM), FCCM Children’s Hospital Los Angeles USA	Ribhi M. Shawar, PhD, D(ABMM) FDA Center for Devices and Radiological Health USA
	Tanis Dingle, PhD, D(ABMM), FCCM Provincial Laboratory for Public Health Canada	

### Working Group on Outreach

<b>Janet A. Hindler, MCLS, MT(ASCP)</b> Co-Chairholder USA	April Abbott, PhD, D(ABMM) Deaconess Hospital Laboratory USA	Romney M. Humphries, PhD, D(ABMM) Accelerate Diagnostics USA
<b>Audrey N. Schuetz, MD, MPH, D(ABMM)</b> Co-Chairholder Mayo Clinic USA	April Bobenchik, PhD, D(ABMM) Lifespan Academic Medical Center USA	Violeta J. Rekasius, BS, MT(ASCP) Loyola University Medical Center USA
<b>Stella Antonara, PhD</b> Committee Secretary Nationwide Children’s Hospital USA	Angella Charnot-Katsikas, MD The University of Chicago USA	Nicole Scangarella-Oman, BS, MS GlaxoSmithKline USA
	Marcelo F. Galas Pan American Health Organization USA	Lars F. Westblade, PhD, D(ABMM) New York Presbyterian Hospital - Weill Cornell Campus USA

### Working Group on Quality Control

<b>Sharon K. Cullen, BS, PMP, RAC</b> Co-Chairholder Beckman Coulter –West Sacramento USA	Dana C. Dressel, MT(ASCP) International Health Management Associates, Inc. USA	Susan D. Munro, CLS, MT(ASCP) USA
<b>Maria M. Traczewski, BS, MT(ASCP)</b> Co-Chairholder The Clinical Microbiology Institute USA	Kerian K. Grande Roche, PhD FDA Center for Devices and Radiological Health USA	Elizabeth Palavecino, MD Wake Forest Baptist Medical Center USA
<b>Michael D. Huband, BS</b> Committee Secretary JMI Laboratories USA	Janet A. Hindler, MCLS, MT(ASCP) USA	Chris Pillar, PhD Micromyx, LLC USA
Patricia S. Conville, MS, MT(ASCP) FDA Center for Devices and Radiological Health USA	Denise Holliday, MT(ASCP) BD Diagnostic Systems USA	Mary K. York, PhD, D(ABMM) MKY Microbiology Consulting USA
	Erika Matuschek, PhD ESCMID Sweden	

## Working Group on Text and Tables

<b>Shelley Campeau, PhD, D(ABMM)</b> <b>Co-Chairholder</b> UCLA Medical Center USA	Peggy Kohner, BS, MT(ASCP) Mayo Clinic USA	Dale A. Schwab, PhD, D(ABMM)CM Quest Diagnostics Nichols Institute USA
<b>Jana M. Swenson, MMSc</b> <b>Co-Chairholder</b> USA	Dyan Luper, BS, MT(ASCP)SM, MB BD Diagnostic Systems USA	Richard B. Thomson, Jr., PhD, D(ABMM), FAAM Evanston Hospital, NorthShore University HealthSystem USA
<b>Carey-Ann Burnham, PhD,</b> <b>D(ABMM)</b> <b>Committee Secretary</b> Washington University School of Medicine USA	Linda M. Mann, PhD, D(ABMM) USA	Maria M. Traczewski, BS, MT(ASCP) The Clinical Microbiology Institute USA
Janet A. Hindler, MCLS, MT(ASCP) USA	Susan D. Munro, CLS, MT(ASCP) USA	Nancy E. Watz, MS, MT(ASCP), CLS Stanford Health Care USA
Melissa Jones, MT(ASCP), CLS UNC Healthcare USA	L. Barth Reller, MD Duke University School of Medicine USA	Mary K. York, PhD, D(ABMM) MKY Microbiology Consulting USA

### Staff

Clinical and Laboratory Standards Institute USA	Megan L. Tertel, MA, ELS <i>Editorial Manager</i>	Kristy L. Leirer, MS <i>Editor</i>
Marcy L. Hackenbrack, MCM, M(ASCP) <i>Project Manager</i>	Catherine E.M. Jenkins <i>Editor</i>	Laura Martin <i>Editor</i>

## Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

## Expert Panel on Microbiology

<b>Richard B. Thomson Jr., PhD,</b> <b>D(ABMM), FAAM</b> <b>Chairholder</b> Evanston Hospital, NorthShore University HealthSystem USA	Carey-Ann Burnham, PhD, D(ABMM) Washington University School of Medicine USA	David H. Pincus, MS, RM/SM(NRCM), SM(ASCP) bioMérieux, Inc. USA
<b>Mary Jane Ferraro, PhD, MPH</b> <b>Vice-Chairholder</b> Massachusetts General Hospital and Harvard Medical School USA	German Esparza, BSc Proasecal SAS Colombia	Audrey N. Schuetz, MD, MPH, D(ABMM) Mayo Clinic USA
Lynette Y. Berkeley, PhD, MT(ASCP) FDA Center for Drug Evaluation and Research USA	Mark G. Papich, DVM, MS College of Veterinary Medicine, North Carolina State University USA	Ribhi M. Shawar, PhD, D(ABMM) FDA Center for Devices and Radiological Health USA
	Jean B. Patel, PhD, D(ABMM) Centers for Disease Control and Prevention USA	Barbara L. Zimmer, PhD Beckman Coulter – West Sacramento USA

## Acknowledgments

CLSI, the Consensus Council, the Subcommittee on Antimicrobial Susceptibility Testing, and the Working Group on M02/M07 Revision gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Patricia Bradford, PhD  
Antimicrobial Development  
Specialists, LLC  
USA

Jennifer Dien Bard, PhD, D(ABMM),  
FCCM  
Children's Hospital Los Angeles  
USA

Beth P. Goldstein, PhD  
Beth Goldstein Consultant  
USA

Karen Bush, PhD  
Indiana University  
USA

CLSI, the Consensus Council, the Subcommittee on Antimicrobial Susceptibility Testing, and the Working Group on M02/M07 Revision gratefully acknowledge the following volunteers for their important contributions to their respective working groups and the development of this standard:

Darcie E. Carpenter, PhD, CIC, CEM  
Beckman Coulter, Inc.  
USA

Audrey N. Schuetz, MD, MPH,  
D(ABMM)  
Mayo Clinic  
USA

Barbara L. Zimmer, PhD  
Beckman Coulter – West Sacramento  
USA

Sandra S. Richter, MD, D(ABMM),  
FCAP, FIDSA  
Cleveland Clinic  
USA

Matthew A. Wikler, MD, FIDSA, MBA  
IDTD Consulting  
USA

CLSI, the Consensus Council, the Subcommittee on Antimicrobial Susceptibility Testing, and the Working Group on M02/M07 Revision gratefully acknowledge the following volunteers for contributing photos to the *M02 Disk Diffusion Reading Guide*<sup>2</sup>:

William Lainhart, PhD  
Washington University School of  
Medicine in St. Louis  
USA

Victoria Anikst, CMS, M(ASCP)  
UCLA Medical Center  
USA

Laura M. Koeth, MT(ASCP)  
Laboratory Specialists, Inc.  
USA

Janet A. Hindler, MCLS, MT(ASCP)  
USA



## Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	xi
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges .....	xiii
CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administration Breakpoints .....	xiv
Subcommittee on Antimicrobial Susceptibility Testing Mission Statement .....	xv
Chapter 1: Introduction .....	1
1.1 Scope .....	1
1.2 Background .....	1
1.3 Standard Precautions .....	2
1.4 Terminology .....	2
Chapter 2: Indications for Performing Antimicrobial Susceptibility Tests .....	7
2.1 Selecting Antimicrobial Agents for Routine Testing and Reporting .....	7
2.2 Routine Reports .....	8
2.3 Antimicrobial Agent Classes .....	8
2.4 Selection Guidelines .....	12
2.5 Suggested Guidelines for Routine and Selective Testing and Reporting .....	12
Chapter 3: Disk Diffusion Antimicrobial Susceptibility Testing Process .....	15
3.1 Disk Diffusion Test Reagents .....	17
3.2 Testing Strains That Fail to Grow Satisfactorily .....	18
3.3 Antimicrobial Disks .....	18
3.4 Preparing Inoculum for Disk Diffusion Tests .....	19
3.5 Inoculating the Test Plates .....	21
3.6 Applying Disks to Inoculated Agar Plates .....	22
3.7 Reading Plates and Interpreting Results .....	22
3.8 Special Considerations for Fastidious Organisms .....	24
3.9 Special Considerations for Detecting Resistance .....	28
3.10 Supplemental (Not Routine) Tests .....	37
3.11 Disk Diffusion Method Limitations .....	39
Chapter 4: Quality Control and Quality Assurance .....	41
4.1 Quality Control Purpose .....	41
4.2 Quality Control Responsibilities .....	42
4.3 Selecting Strains for Quality Control .....	42
4.4 Maintaining and Testing Quality Control Strains .....	43
4.5 Batch or Lot Quality Control .....	43
4.6 Zone Diameter Quality Control Ranges .....	44
4.7 Quality Control Testing Frequency .....	44
4.8 Out-of-Range Results With Quality Control Strains and Corrective Action .....	46
4.9 Reporting Patient Results When Out-of-Range Quality Control Results Are Observed .....	49
4.10 Confirming Results When Testing Patient Isolates .....	49
4.11 End-Point Interpretation Control .....	50

**Contents (Continued)**

Chapter 5: Conclusion.....52

Chapter 6: Supplemental Information.....52

    References.....53

    Appendix A. Preparation of Media and Reagents.....56

    Appendix B. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests .....60

    Appendix C. Quality Control Strain Maintenance.....64

    Appendix D. Quality Control Protocol Flow Charts.....66

    The Quality Management System Approach.....70

    Related CLSI Reference Materials .....71

## Foreword

The most current edition of CLSI document M100,<sup>1</sup> an annually published volume of tables, is made available with this standard to ensure users are aware of the latest recommendations related to the methods described in M02 and CLSI document M07.<sup>3</sup>

Many other editorial and procedural changes in this edition of M02 resulted from Subcommittee on Antimicrobial Susceptibility Testing meetings held since 2015. Specific changes to the tables are summarized at the beginning of M100.<sup>1</sup> The most important changes in M02 are summarized below.

## Overview of Changes

This standard replaces the previous edition of the approved standard, M02-A12, published in 2015. Several changes were made in this edition, including:

- **General:**
  - Harmonized language and information on drug selection and QC with CLSI document M07<sup>3</sup>
  - To harmonize with the International Organization for Standardization, the terms for the methods for inoculum preparation have been changed. “Growth method” has been changed to “broth culture method,” and “direct colony suspension method” has been changed to “colony suspension method” throughout the document
- **Subchapter 1.4.1, Definitions:**
  - Clarified definitions for breakpoint, interpretive category, susceptible, susceptible-dose dependent, intermediate, resistant, nonsusceptible, and quality control
  - Added definitions for minimal inhibitory concentration, routine test, supplemental test, surrogate agent test, CarbaNP test, and modified carbapenem inactivation method
- **Subchapter 1.4.2, Abbreviations and Acronyms:**
  - Deleted abbreviations for  $\beta$ -lactamase types
- **Subchapter 2.3.2.2, Folate Pathway Antagonists:**
  - Revised nomenclature from “folate pathway inhibitor” to “folate pathway antagonist”
- **Subchapter 2.3, Antimicrobial Agent Classes:**
  - Clarified and updated the antimicrobial agent classes
- **Subchapter 3.1.2, Handling and Storing Mueller-Hinton Agar Plates:**
  - Added information on proper storage of Mueller-Hinton agar plates
- **Subchapter 3.7, Reading Plates and Interpreting Results:**
  - Added reference to the *M02 Disk Diffusion Reading Guide*<sup>2</sup>
  - Added instruction to read vancomycin results for *Enterococcus* with transmitted light
- **Subchapter 3.8, Table 1. Testing Considerations for Fastidious Organisms:**
  - Clarified source plate incubation times and inoculum broth for some fastidious organisms
- **Subchapter 3.9, Special Considerations for Detecting Resistance:**
  - Reorganized and streamlined

- Moved Subchapters 3.9.4 (Inducible Clindamycin Resistance) and 3.9.6 ( $\beta$ -Lactamase Tests) to create a new subchapter, 3.10 (Supplemental [Not Routine] Tests)
- **Subchapter 3.9.1, Staphylococci:**
  - Added information for *Staphylococcus pseudintermedius* and *Staphylococcus schleiferi*
  - Reorganized and clarified information for staphylococci
- **Subchapter 3.9.4, Gram-Negative Bacilli:**
  - Expanded and clarified information on  $\beta$ -lactamases
  - Added footnote to Table 4, Enzyme Classifications for  $\beta$ -Lactamases, to clarify the difference between cephalosporin subclasses and generations
  - Updated nomenclature for *Enterobacter aerogenes* to *Klebsiella* (formerly *Enterobacter aerogenes*<sup>4</sup>)
- **Appendixes:**
  - Reorganized to reflect the order in which they are referenced in the main text, as follows:
    - **Appendix A. Preparation of Media and Reagents** (formerly Appendix B)
    - **Appendix B. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests** (formerly Appendix C)
    - **Appendix C. Quality Control Strain Maintenance** (formerly Appendix E)
    - **Appendix D. Quality Control Protocol Flow Charts** (formerly Appendix A)
  - Deleted **Quality Control Strains for Antimicrobial Susceptibility Tests** (formerly Appendix D) (see M100<sup>1</sup> Appendix C)
- **Appendix A. Preparation of Media and Reagents:**
  - Reorganized procedures into step-action tables
- **Appendix B. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests:**
  - Table B1. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests for Nonfastidious Organisms:
    - Added information regarding linezolid and daptomycin for *Staphylococcus* and *Enterococcus*
  - Table B2. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests for Fastidious Organisms:
    - Clarified source plate incubation times for some fastidious organisms
    - Clarified QC for *Haemophilus influenzae* and *Haemophilus parainfluenzae*
    - Clarified oxacillin disk QC when testing *Streptococcus pneumoniae*
- **Appendix C. Quality Control Strain Maintenance:**
  - Clarified maintenance and subculture of QC strains
- **Appendix D. Quality Control Protocol Flow Charts:**
  - Recreated QC flow charts in black-and-white format for easier viewing
  - Revised Appendixes D1 and D2 flow charts

## Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges

The Clinical and Laboratory Standards Institute (CLSI) is an international, voluntary, not-for-profit, interdisciplinary, standards-developing, and educational organization accredited by the American National Standards Institute that develops and promotes the use of consensus-developed standards and guidelines within the health care community. These consensus standards and guidelines are developed in an open and consensus-seeking forum to cover critical areas of diagnostic testing and patient health care. CLSI is open to anyone or any organization that has an interest in diagnostic testing and patient care. Information about CLSI is found at [www.clsi.org](http://www.clsi.org).

The CLSI Subcommittee on Antimicrobial Susceptibility Testing reviews data from a variety of sources and studies (eg, *in vitro*, pharmacokinetics-pharmacodynamics, and clinical studies) to establish antimicrobial susceptibility test methods, breakpoints, and QC parameters. The details of the data necessary to establish breakpoints, QC parameters, and how the data are presented for evaluation are described in CLSI document M23.<sup>5</sup>

Over time, a microorganism's susceptibility to an antimicrobial agent may decrease, resulting in a lack of clinical efficacy and/or safety. In addition, microbiological methods and QC parameters may be refined to ensure more accurate and better performance of susceptibility test methods. Because of these types of changes, CLSI continually monitors and updates information in its documents. Although CLSI standards and guidelines are developed using the most current information available at the time, the field of science and medicine is always changing; therefore, standards and guidelines should be used in conjunction with clinical judgment, current knowledge, and clinically relevant laboratory test results to guide patient treatment.

Additional information, updates, and changes in this standard are found in the meeting summary minutes of the Subcommittee on Antimicrobial Susceptibility Testing at [www.clsi.org](http://www.clsi.org).

## **CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administration Breakpoints**

It is important for users of M02, M07,<sup>3</sup> and the M100<sup>1</sup> supplement to recognize that the standard methods described in CLSI documents are reference methods. These methods may be used for routine antimicrobial susceptibility testing of patient isolates, for evaluating commercial devices that will be used in medical laboratories, or by drug or device manufacturers for testing of new agents or systems. Results generated by reference methods, such as those contained in CLSI documents, may be used by regulatory authorities to evaluate the performance of commercial susceptibility testing devices as part of the approval process. Clearance by a regulatory authority indicates the commercial susceptibility testing device provides susceptibility results that are substantially equivalent to results generated using reference methods for the organisms and antimicrobial agents described in the device manufacturer's approved package insert.

CLSI breakpoints may differ from those approved by various regulatory authorities for many reasons, including use of different databases, differences in data interpretation, differences in doses used in different parts of the world, and public health policies. Differences also exist because CLSI proactively evaluates the need for changing breakpoints. The reasons why breakpoints may change and the manner in which CLSI evaluates data and determines breakpoints are outlined in CLSI document M23.<sup>5</sup>

Following a decision by CLSI to change an existing breakpoint, regulatory authorities may also review data to determine how changing breakpoints may affect the safety and effectiveness of the antimicrobial agent for the approved indications. If the regulatory authority changes breakpoints, commercial device manufacturers may have to conduct a clinical trial, submit the data to the regulatory authority, and await review and approval. For these reasons, a delay of one or more years may be needed if a breakpoint and interpretive category change is to be implemented by a device manufacturer. In the United States, it is acceptable for laboratories that use US Food and Drug Administration (FDA)–cleared susceptibility testing devices to use existing FDA breakpoints. Either FDA or CLSI susceptibility breakpoints are acceptable to laboratory accrediting organizations in the United States. Policies in other countries may vary. Each laboratory should check with the manufacturer of its antimicrobial susceptibility test system for additional information on the breakpoints and interpretive categories used in its system's software.

Following discussions with appropriate stakeholders (eg, infectious diseases and pharmacy practitioners, the pharmacy and therapeutics and infection control committees of the medical staff, and antimicrobial stewardship teams), newly approved or revised breakpoints may be implemented by laboratories. Following verification, CLSI disk diffusion test breakpoints may be implemented as soon as they are published in M100.<sup>1</sup> If a device includes antimicrobial test concentrations sufficient to allow interpretation of susceptibility and resistance to an agent using the CLSI breakpoints, a laboratory could choose to, after appropriate verification, interpret and report results using CLSI breakpoints.

## Subcommittee on Antimicrobial Susceptibility Testing Mission Statement

The Subcommittee on Antimicrobial Susceptibility Testing is composed of representatives from the professions, government, and industry, including microbiology laboratories, government agencies, health care providers and educators, and pharmaceutical and diagnostic microbiology industries. Using the CLSI voluntary consensus process, the subcommittee develops standards that promote accurate antimicrobial susceptibility testing and appropriate reporting. The mission of the Subcommittee on Antimicrobial Susceptibility Testing is to:

- Develop standard reference methods for antimicrobial susceptibility tests.
- Provide quality control parameters for standard test methods.
- Establish breakpoints for the results of standard antimicrobial susceptibility tests and provide epidemiological cutoff values when breakpoints are not available.
- Provide suggestions for testing and reporting strategies that are clinically relevant and cost-effective.
- Continually refine standards and optimize detection of emerging resistance mechanisms through development of new or revised methods, breakpoints, and quality control parameters.
- Educate users through multimedia communication of standards and guidelines.
- Foster a dialogue with users of these methods and those who apply them.

The ultimate purpose of the subcommittee's mission is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care. The standards and guidelines are meant to be comprehensive and to include all antimicrobial agents for which the data meet established CLSI guidelines. The values that guide this mission are quality, accuracy, fairness, timeliness, teamwork, consensus, and trust.

**NOTE:** The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### Key Words

Agar diffusion, antibiotic, antimicrobial agents, disk diffusion, Kirby-Bauer, susceptibility testing



# Performance Standards for Antimicrobial Disk Susceptibility Tests

## Chapter 1: Introduction

This chapter includes:

- Standard's scope and applicable exclusions
- Background information pertinent to the standard's content
- Standard precautions information
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

### 1.1 Scope

This standard describes the reference agar disk diffusion method used to determine the *in vitro* antimicrobial susceptibility of bacteria that grow aerobically and includes:

- Agar plate preparation
- Testing conditions, including inoculum preparation and standardization, incubation time, and incubation temperature
- Results interpretation
- QC procedures
- Disk diffusion method limitations

To assist the medical laboratory, suggestions are provided for selecting antimicrobial agents for routine testing and reporting.

Standards for testing the *in vitro* antimicrobial susceptibility of bacteria that grow aerobically using dilution methods are found in CLSI document M07.<sup>3</sup> Standards for testing the *in vitro* antimicrobial susceptibility of bacteria that grow anaerobically are found in CLSI document M11.<sup>6</sup> Guidelines for standardized antimicrobial susceptibility testing (AST) of infrequently isolated or fastidious bacteria that are not included in CLSI documents M02, M07,<sup>3</sup> or M11<sup>6</sup> are available in CLSI document M45.<sup>7</sup> The AST methods provided in this standard can be used in laboratories around the world including but not limited to:

- Medical laboratories
- Public health laboratories
- Research laboratories
- Food laboratories
- Environmental laboratories

### 1.2 Background

Various laboratory methods can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. In many medical microbiology laboratories, an agar disk diffusion method is used routinely for testing common, rapidly growing, and certain fastidious bacterial pathogens. This standard describes the performance, applications, and limitations of the standardized disk diffusion test method. Recommendations<sup>8</sup> and governmental regulations<sup>9,10</sup> proposed by the US Food and Drug Administration